Prior to joining Alvotech, Jayanth had close to 20 years of experience in biopharmaceutical large-scale manufacturing. He spent 11 years working for Merck and BioMarin in the US, where he was associated with the commercial launch and manufacturing of Gardasil, commercial manufacturing support for Recombivax and commercial manufacturing for Naglazyme and Aldurazyme (using perfusion CHO cell culture).
For the last seven years, Jayanth focused on biosimilar development and manufacturing at Biocon and Cipla Biotec, where the highlight was the commercial launch of Canmab/Hertraz (biosimilar Trastuzumab) and Alzumab, and clinical manufacturing of biosimilar Bevacizumab, Adalimumab and Peg-filgrastim. Over the course of 18 years, Jayanth has led groups responsible for design, qualification and validation of stainless steel as well as single-use drug substance facilities that have met the requirements of both the FDA and EMA for clinical and commercial manufacturing of both vaccines and monoclonal antibodies.
He has a Ph.D. in Biochemical Engineering from the University of Georgia at Athens, USA and is actively involved in the Biotechnology division of the American Chemical Society and the PDA USA and India Chapters. Jayanth’s appointment to Alvotech marked another important step forward in our pioneering efforts in specialty Biogenerics, towards the creation of a global leader in high-quality biopharmaceuticals.